High prevalence of atherosclerosis and arterial calcifca-tion in chronic kidney disease is far beyond the explana-tion by common cardiovascular risk factors such as aging diabetes, hypertension and dyslipidemia. The m...High prevalence of atherosclerosis and arterial calcifca-tion in chronic kidney disease is far beyond the explana-tion by common cardiovascular risk factors such as aging diabetes, hypertension and dyslipidemia. The magnitude of coronary artery calcification is independently and inversely associated with renal function. In addition to cardiovascular risk factors, other chronic kidney disease-related risks such as phosphate retention, excess of calcium and prolonged dialysis vintage also contribute to the development of vascular calcifcation. Strategies to lower vascular calcifcation burden in chronic kidney dis-ease population should include minimizing chronic kidney disease and atherosclerotic risk factors. Current therapies available are non-calcium containing phosphate bind-ers, low dose active vitamin D and calcimimetic agent. The role of bisphosphonates in vascular calcification in chronic kidney disease population remains unclear. Preliminary data on sodium thiosulfate are promising, however, larger studies on effcacy and patient outcomes are necessary. Several large randomized controlled trials have confrmed the lack of beneft of statin in attenuat-ing the progression of vascular calcifcation.展开更多
Facing the needs of an increasingly ageing population is rapidly becoming a major public health issue in western countries, Chronic kidney disease （CKD）, whose current prevalence is estimated around 10%-15% in the g...Facing the needs of an increasingly ageing population is rapidly becoming a major public health issue in western countries, Chronic kidney disease （CKD）, whose current prevalence is estimated around 10%-15% in the general population, with considerably higher figures in at-risk groups, is widely known to increase with age. In the elderly, renal impairment is often concomitant or secondary to several other systemic disorders such as hypertension, atherosclerosis,展开更多
基金supported by National Basic Research Development Program of China(No.2012CB26611)the National Natural Science Foundation of China(No.31260247)+2 种基金the Science and Technology Research Project of Xinjiang Production and Construction CorpsChina(No.2012BA0212010GG34)
文摘High prevalence of atherosclerosis and arterial calcifca-tion in chronic kidney disease is far beyond the explana-tion by common cardiovascular risk factors such as aging diabetes, hypertension and dyslipidemia. The magnitude of coronary artery calcification is independently and inversely associated with renal function. In addition to cardiovascular risk factors, other chronic kidney disease-related risks such as phosphate retention, excess of calcium and prolonged dialysis vintage also contribute to the development of vascular calcifcation. Strategies to lower vascular calcifcation burden in chronic kidney dis-ease population should include minimizing chronic kidney disease and atherosclerotic risk factors. Current therapies available are non-calcium containing phosphate bind-ers, low dose active vitamin D and calcimimetic agent. The role of bisphosphonates in vascular calcification in chronic kidney disease population remains unclear. Preliminary data on sodium thiosulfate are promising, however, larger studies on effcacy and patient outcomes are necessary. Several large randomized controlled trials have confrmed the lack of beneft of statin in attenuat-ing the progression of vascular calcifcation.
文摘Facing the needs of an increasingly ageing population is rapidly becoming a major public health issue in western countries, Chronic kidney disease （CKD）, whose current prevalence is estimated around 10%-15% in the general population, with considerably higher figures in at-risk groups, is widely known to increase with age. In the elderly, renal impairment is often concomitant or secondary to several other systemic disorders such as hypertension, atherosclerosis,
